PRX302

DRUG6 trials

Sponsors

Sophiris Bio Corp

Conditions

Benign Prostatic HyperplasiaLocally Recurrent Prostate CancerProstate Cancer

Phase 1

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

CompletedNCT01454349

Sophiris Bio CorpBenign Prostatic Hyperplasia

Start: 2011-09-30End: 2013-08-31Updated: 2013-08-21

Phase 2

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

CompletedNCT00686088

Sophiris Bio CorpLocally Recurrent Prostate Cancer

Start: 2008-02-29End: 2009-09-30Target: 30Updated: 2009-10-29

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia

CompletedNCT00889707

Sophiris Bio CorpBenign Prostatic Hyperplasia

Start: 2009-01-31End: 2010-09-30Updated: 2018-11-21

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

CompletedNCT02499848

Sophiris Bio CorpProstate Cancer

Start: 2015-07-31End: 2016-06-30Updated: 2016-07-27

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

CompletedNCT03081481

Sophiris Bio CorpProstate Cancer

Start: 2017-06-07End: 2019-04-05Updated: 2019-04-10

Phase 3

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

CompletedNCT01966614

Sophiris Bio CorpBenign Prostatic Hyperplasia

Start: 2013-10-31End: 2015-12-31Updated: 2017-04-27